Both Invega Sustenna and Methylphenidate offer similar effectiveness in symptom control, with the main difference being how quickly they act. Either drug is a viable option depending on the patient’s needs.

Both Invega Sustenna and Methylphenidate have similar safety profiles, with mild and transient side effects. Neither presents significant long-term safety concerns.

Methylphenidate has a more stable therapeutic effect and is less likely to lead to dependency or cravings compared to Invega Sustenna.

Invega Sustenna offers the convenience of a once-daily dose, simplifying treatment adherence for patients.

Invega Sustenna has fewer contraindications, making it suitable for a broader range of patients, including those with comorbidities.

Both drugs offer advantages depending on treatment goals. Invega Sustenna is great for fast relief, while Methylphenidate is better for long-term management. The choice depends on the patient’s specific needs.